Effective strategies of vaccine prioritization are essential to mitigate the impacts of severe infectious diseases. We investigate the role of infection fatality ratio (IFR) and social contact matrices on vaccination prioritization using a compartmental epidemic model fueled by real-world data of different diseases and countries. Our study confirms that massive and early vaccination is extremely effective to reduce the disease fatality if the contagion is mitigated, but the effectiveness is increasingly reduced as vaccination beginning delays in an uncontrolled epidemiological scenario. The optimal and least effective prioritization strategies depend non-linearly on epidemiological variables. Regions of the epidemiological parameter space, in which prioritizing the most vulnerable population is more effective than the most contagious individuals, depend strongly on the IFR age profile being, for example, substantially broader for COVID-19 in comparison with seasonal influenza. Demographics and social contact matrices deform the phase diagrams but do not alter their qualitative shapes.
REFERENCES
1.
S.
Moore
, E. M.
Hill
, M. J.
Tildesley
, L.
Dyson
, and M. J.
Keeling
, “Vaccination and non-pharmaceutical interventions for COVID-19: A mathematical modelling study
,” Lancet Infect. Dis.
21
, 793
–802
(2021
). 2.
C. J.
Worby
and H.-H.
Chang
, “Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic
,” Nat. Commun.
11
, 4049
(2020
). 3.
P. C.
Ventura
, A.
Aleta
, F. A.
Rodrigues
, and Y.
Moreno
, “Modeling the effects of social distancing on the large-scale spreading of diseases
,” Epidemics
38
, 100544
(2022
). 4.
S.
Pei
, S.
Kandula
, and J.
Shaman
, “Differential effects of intervention timing on COVID-19 spread in the United States
,” Sci. Adv.
6
, eabd6370
(2020
). 5.
Y.
Bo
, C.
Guo
, C.
Lin
, Y.
Zeng
, H. B.
Li
, Y.
Zhang
, M. S.
Hossain
, J. W.
Chan
, D. W.
Yeung
, K. O.
Kwok
, S. Y.
Wong
, A. K.
Lau
, and X. Q.
Lao
, “Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020
,” Int. J. Infect. Dis.
102
, 247
–253
(2021
). 6.
R.
Vardavas
, A.
Strong
, J.
Bouey
, J.
Welburn
, P.
de Lima
, L.
Baker
, K.
Zhu
, M.
Priest
, L.
Hu
, and J.
Ringel
, The Health and Economic Impacts of Nonpharmaceutical Interventions to Address COVID-19: A Decision Support Tool for State and Local Policymakers
(RAND Corporation
, 2020
).7.
T.
Alpert
, A. F.
Brito
, E.
Lasek-Nesselquist
, J.
Rothman
, A. L.
Valesano
, M. J.
MacKay
, M. E.
Petrone
, M. I.
Breban
, A. E.
Watkins
, C. B.
Vogels
, C. C.
Kalinich
, S.
Dellicour
, A.
Russell
, J. P.
Kelly
, M.
Shudt
, J.
Plitnick
, E.
Schneider
, W. J.
Fitzsimmons
, G.
Khullar
, J.
Metti
, J. T.
Dudley
, M.
Nash
, N.
Beaubier
, J.
Wang
, C.
Liu
, P.
Hui
, A.
Muyombwe
, R.
Downing
, J.
Razeq
, S. M.
Bart
, A.
Grills
, S. M.
Morrison
, S.
Murphy
, C.
Neal
, E.
Laszlo
, H.
Rennert
, M.
Cushing
, L.
Westblade
, P.
Velu
, A.
Craney
, L.
Cong
, D. R.
Peaper
, M. L.
Landry
, P. W.
Cook
, J. R.
Fauver
, C. E.
Mason
, A. S.
Lauring
, K. S.
George
, D. R.
MacCannell
, and N. D.
Grubaugh
, “Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States
,” Cell
184
, 2595
–2604
(2021
). 8.
M.
Alene
, L.
Yismaw
, M. A.
Assemie
, D. B.
Ketema
, W.
Gietaneh
, and T. Y.
Birhan
, “Serial interval and incubation period of COVID-19: A systematic review and meta-analysis
,” BMC Infect. Dis.
21
, 257
(2021
). 9.
D.
Planas
, T.
Bruel
, L.
Grzelak
, F.
Guivel-Benhassine
, I.
Staropoli
, F.
Porrot
, C.
Planchais
, J.
Buchrieser
, M. M.
Rajah
, E.
Bishop
, M.
Albert
, F.
Donati
, M.
Prot
, S.
Behillil
, V.
Enouf
, M.
Maquart
, M.
Smati-Lafarge
, E.
Varon
, F.
Schortgen
, L.
Yahyaoui
, M.
Gonzalez
, J. D.
Sèze
, H.
Péré
, D.
Veyer
, A.
Sève
, E.
Simon-Lorière
, S.
Fafi-Kremer
, K.
Stefic
, H.
Mouquet
, L.
Hocqueloux
, S.
van der Werf
, T.
Prazuck
, and O.
Schwartz
, “Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
,” Nat. Med.
27
, 917
–924
(2021
). 10.
F. G.
Naveca
, V.
Nascimento
, V. C.
de Souza
, A.
de Lima Corado
, F.
Nascimento
, G.
Silva
, Á.
Costa
, D.
Duarte
, K.
Pessoa
, M.
Mejía
, M. J.
Brandão
, M.
Jesus
, L.
Gonçalves
, C. F.
da Costa
, V.
Sampaio
, D.
Barros
, M.
Silva
, T.
Mattos
, G.
Pontes
, L.
Abdalla
, J. H.
Santos
, I.
Arantes
, F. Z.
Dezordi
, M. M.
Siqueira
, G. L.
Wallau
, P. C.
Resende
, E.
Delatorre
, T.
Gräf
, and G.
Bello
, “COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence
,” Nat. Med.
27
, 1230
–1238
(2021
). 11.
W.
Zhou
and W.
Wang
, “Fast-spreading SARS-CoV-2 variants: Challenges to and new design strategies of COVID-19 vaccines
,” Signal Transduct. Target. Ther.
6
, 226
(2021
). 12.
F.
Campbell
, B.
Archer
, H.
Laurenson-Schafer
, Y.
Jinnai
, F.
Konings
, N.
Batra
, B.
Pavlin
, K.
Vandemaele
, M. D. V.
Kerkhove
, T.
Jombart
, O.
Morgan
, and O.
le Polain de Waroux
, “Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021
,” Eurosurveillance
26
, 2100509
(2021
). 13.
K.
Kupferschmidt
and M.
Wadman
, “Delta variant triggers new phase in the pandemic
,” Science
372
, 1375
–1376
(2021
). 14.
P. R.
Matt
and J.
Keeling
, Modeling Infectious Diseases in Humans and Animals
(Princeton University Press
, 2007
).15.
D.
Sridhar
and D.
Gurdasani
, “Herd immunity by infection is not an option
,” Science
371
, 230
–231
(2021
). 16.
P. M.
Heaton
, “The Covid-19 vaccine-development multiverse
,” N. Engl. J. Med.
383
, 1986
–1988
(2020
). 17.
P.
Ball
, “The lightning-fast quest for COVID vaccines—And what it means for other diseases
,” Nature
589
, 16
–18
(2021
). 18.
R.
Palacios
, A. P.
Batista
, C. S. N.
Albuquerque
, E. G.
Patiño
, J.
do Prado Santos
, M. T. R. P.
Conde
, R.
de Oliveira Piorelli
, L. C. P.
Júnior
, S. M.
Raboni
, F.
Ramos
, G. A. S.
Romero
, F. E.
Leal
, L. F. A.
Camargo
, F. H.
Aoki
, E. B.
Coelho
, D. S.
Oliveira
, C. J. F.
Fontes
, G. C. S.
Pileggi
, A. L. L.
de Oliveira
, A. M.
de Siqueira
, D. B. L.
de Oliveira
, V. F.
Botosso
, G.
Zeng
, Q.
Xin
, M. M.
Teixeira
, M. L.
Nogueira
, and E. G.
Kallas
, “Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV study
,” SSRN Electron. J.
(published online 2021).19.
I.
Yelin
, R.
Katz
, E.
Herzel
, T.
Berman-Zilberstein
, A.
Ben-Tov
, J.
Kuint
, S.
Gazit
, T.
Patalon
, G.
Chodick
, and R.
Kishony
, “Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities,” medRxiv (2021).20.
A.
Jara
, E. A.
Undurraga
, C.
González
, F.
Paredes
, T.
Fontecilla
, G.
Jara
, A.
Pizarro
, J.
Acevedo
, K.
Leo
, F.
Leon
, C.
Sans
, P.
Leighton
, P.
Suárez
, H.
Garc'a-Escorza
, and R.
Araos
, “Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
,” N. Engl. J. Med.
385
, 875
–884
(2021
). 21.
O. T.
Ranzani
, M. D. T.
Hitchings
, M.
Dorion
, T. L.
D’Agostini
, R. C.
de Paula
, O. F. P.
de Paula
, E. F. D. M.
Villela
, M. S. S.
Torres
, S. B.
de Oliveira
, W.
Schulz
, M.
Almiron
, R.
Said
, R. D.
de Oliveira
, P.
Vieira da Silva
, W. N.
de Araújo
, J. C.
Gorinchteyn
, J. R.
Andrews
, D. A. T.
Cummings
, A. I.
Ko
, and J.
Croda
, “Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: Test negative case-control study
,” BMJ
374
, n2015
(2021
). 22.
R. W.
Frenck
, N. P.
Klein
, N.
Kitchin
, A.
Gurtman
, J.
Absalon
, S.
Lockhart
, J. L.
Perez
, E. B.
Walter
, S.
Senders
, R.
Bailey
, K. A.
Swanson
, H.
Ma
, X.
Xu
, K.
Koury
, W. V.
Kalina
, D.
Cooper
, T.
Jennings
, D. M.
Brandon
, S. J.
Thomas
, O.
Türeci
, D. B.
Tresnan
, S.
Mather
, P. R.
Dormitzer
, U.
Şahin
, K. U.
Jansen
, and W. C.
Gruber
, “Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents
,” N. Engl. J. Med.
385
, 239
–250
(2021
). 23.
J. R.
Goldstein
, T.
Cassidy
, and K. W.
Wachter
, “Vaccinating the oldest against COVID-19 saves both the most lives and most years of life
,” Proc. Natl. Acad. Sci. U.S.A.
118
, e2026322118
(2021
). 24.
M. C.
Fitzpatrick
and A. P.
Galvani
, “Optimizing age-specific vaccination
,” Science
371
, 890
–891
(2021
). 25.
L.
Matrajt
, J.
Eaton
, T.
Leung
, and E. R.
Brown
, “Vaccine optimization for COVID-19: Who to vaccinate first?
,” Sci. Adv.
7
, eabf1374
(2021
). 26.
M.
Moret
, T. R.
Filho
, J.
Mendes
, T.
Murari
, A. N.
Filho
, A.
Cordeiro
, W.
Ramalho
, F.
Scorza
, and A.-C.
Almeida
, “WHO vaccination protocol can be improved to save more lives,” Res. Sq.
(2021). 27.
L.
Matrajt
, J.
Eaton
, T.
Leung
, D.
Dimitrov
, J. T.
Schiffer
, D. A.
Swan
, and H.
Janes
, “Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination
,” Nat. Commun.
12
, 3449
(2021
). 28.
S. L.
Li
, R. H. M.
Pereira
, C. A.
Prete
, Jr., A. E.
Zarebski
, L.
Emanuel
, P. J. H.
Alves
, P. S.
Peixoto
, C. K. V.
Braga
, A. A.
de Souza Santos
, W. M.
de Souza
, R. J.
Barbosa
, L. F.
Buss
, A.
Mendrone
, C.
de Almeida-Neto
, S. C.
Ferreira
, N. A.
Salles
, I.
Marcilio
, C.-H.
Wu
, N.
Gouveia
, V. H.
Nascimento
, E. C.
Sabino
, N. R.
Faria
, and J. P.
Messina
, “Higher risk of death from COVID-19 in low-income and non-white populations of São Paulo, Brazil
,” BMJ Global Health
6
, e004959
(2021
). 29.
E. J.
Emanuel
, G.
Persad
, A.
Kern
, A.
Buchanan
, C.
Fabre
, D.
Halliday
, J.
Heath
, L.
Herzog
, R. J.
Leland
, E. T.
Lemango
, F.
Luna
, M. S.
McCoy
, O. F.
Norheim
, T.
Ottersen
, G. O.
Schaefer
, K.-C.
Tan
, C. H.
Wellman
, J.
Wolff
, and H. S.
Richardson
, “An ethical framework for global vaccine allocation
,” Science
369
, 1309
–1312
(2020
). 30.
C.
Buckee
, A.
Noor
, and L.
Sattenspiel
, “Thinking clearly about social aspects of infectious disease transmission
,” Nature
595
, 205
–213
(2021
). 31.
M. C.
Castro
and B.
Singer
, “Prioritizing COVID-19 vaccination by age
,” Proc. Natl. Acad. Sci. U.S.A.
118
, e2103700118
(2021
). 32.
G.
Giordano
, M.
Colaneri
, A. D.
Filippo
, F.
Blanchini
, P.
Bolzern
, G. D.
Nicolao
, P.
Sacchi
, P.
Colaneri
, and R.
Bruno
, “Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy
,” Nat. Med.
27
, 993
–998
(2021
). 33.
K. M.
Bubar
, K.
Reinholt
, S. M.
Kissler
, M.
Lipsitch
, S.
Cobey
, Y. H.
Grad
, and D. B.
Larremore
, “Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
,” Science
371
, 916
–921
(2021
). 34.
J. H.
Buckner
, G.
Chowell
, and M. R.
Springborn
, “Optimal dynamic prioritization of scarce COVID-19 vaccines,” medRxiv
(2020). 35.
J.
Molla
, A. P.
de León Chávez
, T.
Hiraoka
, T.
Ala-Nissila
, M.
Kivelä
, and L.
Leskelä
, “Adaptive and optimized COVID-19 vaccination strategies across geographical regions and age groups
,” PLOS Comput. Biol.
18
, e1009974
(2022
). 36.
O.
Milman
, I.
Yelin
, N.
Aharony
, R.
Katz
, E.
Herzel
, A.
Ben-Tov
, J.
Kuint
, S.
Gazit
, G.
Chodick
, T.
Patalon
, and R.
Kishony
, “Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
,” Nat. Med.
27
, 1367
–1369
(2021
). 37.
R.
Pastor-Barriuso
, B.
Pérez-Gómez
, M. A.
Hernán
, M.
Pérez-Olmeda
, R.
Yotti
, J.
Oteo-Iglesias
, J. L.
Sanmartín
, I.
León-Gómez
, A.
Fernández-Garc'a
, P.
Fernández-Navarro
, I.
Cruz
, M.
Martín
, C.
Delgado-Sanz
, N. F.
de Larrea
, J. L.
Paniagua
, J. F.
Muñoz-Montalvo
, F.
Blanco
, A.
Larrauri
, and M.
Pollán
, “Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: Nationwide seroepidemiological study
,” BMJ
371
, m4509
(2020
). 38.
J. P. A.
Ioannidis
, “Infection fatality rate of COVID-19 inferred from seroprevalence data
,” Bull. World Health Organ.
99
, 19
–33
(2021
). 39.
S.
Mallapaty
, “How deadly is the coronavirus? Scientists are close to an answer
,” Nature
582
, 467
–468
(2020
). 40.
I. R.
Barbosa
, M. H. R.
Galvão
, T. A.
de Souza
, S. M.
Gomes
, A.
de Almeida Medeiros
, and K. C.
de Lima
, “Incidence of and mortality from COVID-19 in the older Brazilian population and its relationship with contextual indicators: An ecological study
,” Rev. Bras. Geriatr. Gerontol.
23
, e200171
(2020
). 41.
M. C.
Castro
, S.
Gurzenda
, E. M.
Macário
, and G. V. A.
França
, “Characteristics, outcomes and risk factors for mortality of 522 167 patients hospitalised with COVID-19 in Brazil: A retrospective cohort study
,” BMJ Open
11
, e049089
(2021
). 42.
P.
Poletti
, M.
Tirani
, D.
Cereda
, F.
Trentini
, G.
Guzzetta
, V.
Marziano
, S.
Buoro
, S.
Riboli
, L.
Crottogini
, R.
Piccarreta
, A.
Piatti
, G.
Grasselli
, A.
Melegaro
, M.
Gramegna
, M.
Ajelli
, and S.
Merler
, “Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020
,” Eurosurveillance
25
, 2001383
(2020
). 43.
A. T.
Levin
, W. P.
Hanage
, N.
Owusu-Boaitey
, K. B.
Cochran
, S. P.
Walsh
, and G.
Meyerowitz-Katz
, “Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications
,” Eur. J. Epidemiol.
35
, 1123
–1138
(2020
). 44.
R.
Verity
, L. C.
Okell
, I.
Dorigatti
, P.
Winskill
, C.
Whittaker
, N.
Imai
, G.
Cuomo-Dannenburg
, H.
Thompson
, P. G. T.
Walker
, H.
Fu
, A.
Dighe
, J. T.
Griffin
, M.
Baguelin
, S.
Bhatia
, A.
Boonyasiri
, A.
Cori
, Z.
Cucunubá
, R.
FitzJohn
, K.
Gaythorpe
, W.
Green
, A.
Hamlet
, W.
Hinsley
, D.
Laydon
, G.
Nedjati-Gilani
, S.
Riley
, S.
van Elsland
, E.
Volz
, H.
Wang
, Y.
Wang
, X.
Xi
, C. A.
Donnelly
, A. C.
Ghani
, and N. M.
Ferguson
, “Estimates of the severity of coronavirus disease 2019: A model-based analysis
,” Lancet Infect. Dis.
20
, 669
–677
(2020
). 45.
Centers for Disease Control and Prevention, “Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States—2018–2019 influenza season,” https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm (2020).
46.
N. G.
Davies
, P.
Klepac
, Y.
Liu
, K.
Prem
, M.
Jit
, C. A. B.
Pearson
, B. J.
Quilty
, A. J.
Kucharski
, H.
Gibbs
, S.
Clifford
, A.
Gimma
, K.
van Zandvoort
, J. D.
Munday
, C.
Diamond
, W. J.
Edmunds
, R. M. G. J.
Houben
, J.
Hellewell
, T. W.
Russell
, S.
Abbott
, S.
Funk
, N. I.
Bosse
, Y. F.
Sun
, S.
Flasche
, A.
Rosello
, C. I.
Jarvis
, and R. M.
Eggo
, “Age-dependent effects in the transmission and control of COVID-19 epidemics
,” Nat. Med.
26
, 1205
–1211
(2020
). 47.
K. E.
Johnson
, M.
Lachmann
, M.
Stoddard
, R.
Pasco
, S. J.
Fox
, L. A.
Meyers
, and A.
Chakravarty
, “Detecting in-school transmission of SARS-CoV-2 from case ratios and documented clusters,” medRxiv
(2021). 48.
M.
Cevik
and S. D.
Baral
, “Networks of SARS-CoV-2 transmission
,” Science
373
, 162
–163
(2021
). 49.
J. M.
Epstein
, E.
Hatna
, and J.
Crodelle
, “Triple contagion: A two-fears epidemic model
,” J. R. Soc. Interface
18
, 20210186
(2021
). 50.
K.
Prem
, A. R.
Cook
, and M.
Jit
, “Projecting social contact matrices in 152 countries using contact surveys and demographic data
,” PLoS Comput. Biol.
13
, e1005697
(2017
). 51.
Z.
Wang
, C. T.
Bauch
, S.
Bhattacharyya
, A.
d’Onofrio
, P.
Manfredi
, M.
Perc
, N.
Perra
, M.
Salathé
, and D.
Zhao
, “Statistical physics of vaccination
,” Phys. Rep.
664
, 1
–113
(2016
). 52.
Projeções da População: Brasil e Unidades da Federação, Revisão 2018, 2nd ed., Séries Relatórios Metodológicos No. Vol. 40, edited by Instituto Brasileiro de Geografia e Estatística (IBGE, Instituto Brasileiro de Geografia e Estatística, Rio de Janeiro, 2018).
53.
United Nations, World Population Prospects 2019 (Department of Economic and Social Affairs, Population Division, 2019).
54.
J.
Medlock
and A. P.
Galvani
, “Optimizing influenza vaccine distribution
,” Science
325
, 1705
–1708
(2009
). 55.
Q.
Li
, X.
Guan
, P.
Wu
, X.
Wang
, L.
Zhou
, Y.
Tong
, R.
Ren
, K. S.
Leung
, E. H.
Lau
, J. Y.
Wong
, X.
Xing
, N.
Xiang
, Y.
Wu
, C.
Li
, Q.
Chen
, D.
Li
, T.
Liu
, J.
Zhao
, M.
Liu
, W.
Tu
, C.
Chen
, L.
Jin
, R.
Yang
, Q.
Wang
, S.
Zhou
, R.
Wang
, H.
Liu
, Y.
Luo
, Y.
Liu
, G.
Shao
, H.
Li
, Z.
Tao
, Y.
Yang
, Z.
Deng
, B.
Liu
, Z.
Ma
, Y.
Zhang
, G.
Shi
, T. T.
Lam
, J. T.
Wu
, G. F.
Gao
, B. J.
Cowling
, B.
Yang
, G. M.
Leung
, and Z.
Feng
, “Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia
,” N. Engl. J. Med.
382
, 1199
–1207
(2020
). 56.
S.
Zhang
, M.
Diao
, W.
Yu
, L.
Pei
, Z.
Lin
, and D.
Chen
, “Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the diamond princess cruise ship: A data-driven analysis
,” Int. J. Infect. Dis.
93
, 201
–204
(2020
). 57.
R.
Li
, S.
Pei
, B.
Chen
, Y.
Song
, T.
Zhang
, W.
Yang
, and J.
Shaman
, “Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)
,” Science
368
, 489
–493
(2020
). 58.
S.
Sanche
, Y. T.
Lin
, C.
Xu
, E.
Romero-Severson
, N.
Hengartner
, and R.
Ke
, “High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2
,” Emerg. Infect. Dis.
26
, 1470
–1477
(2020
). 59.
T.
Cerqueira-Silva
, V.
de Araújo Oliveira
, V. S.
Boaventura
, J. M.
Pescarini
, J. B.
Júnior
, T. M.
Machado
, R.
Flores-Ortiz
, G. O.
Penna
, M. Y.
Ichihara
, J. V.
de Barros
, M. L.
Barreto
, G. L.
Werneck
, and M.
Barral-Netto
, “Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
,” Lancet Reg. Health Am.
6
, 100154
(2022
). 60.
M.
Levine-Tiefenbrun
, I.
Yelin
, R.
Katz
, E.
Herzel
, Z.
Golan
, L.
Schreiber
, T.
Wolf
, V.
Nadler
, A.
Ben-Tov
, J.
Kuint
, S.
Gazit
, T.
Patalon
, G.
Chodick
, and R.
Kishony
, “Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
,” Nat. Med.
27
, 790
–792
(2021
). 61.
J. M.
Read
, J. R. E.
Bridgen
, D. A. T.
Cummings
, A.
Ho
, and C. P.
Jewell
, “Novel coronavirus 2019-nCoV (COVID-19): Early estimation of epidemiological parameters and epidemic size estimates
,” Philos. Trans. R. Soc. London, Ser. B
376
, 20200265
(2021
). 62.
L.
Danon
, E.
Brooks-Pollock
, M.
Bailey
, and M.
Keeling
, “A spatial model of COVID-19 transmission in England and Wales: Early spread, peak timing and the impact of seasonality
,” Philos. Trans. R. Soc. London, Ser. B
376
, 20200272
(2021
). 63.
G.
Chodick
, L.
Tene
, T.
Patalon
, S.
Gazit
, A. B.
Tov
, D.
Cohen
, and K.
Muhsen
, “Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization
,” JAMA Netw. Open
4
, e2115985
(2021
). 64.
B. F.
Maier
, A.
Burdinski
, A. H.
Rose
, F.
Schlosser
, D.
Hinrichs
, C.
Betsch
, L.
Korn
, P.
Sprengholz
, M.
Meyer-Hermann
, T.
Mitra
, K.
Lauterbach
, and D.
Brockmann
, “Potential benefits of delaying the second mRNA COVID-19 vaccine dose,” arXiv:2102.13600 (2021).65.
A.
Schulenburg
, W.
cota
, G. S.
Costa
, and S. C.
Ferreira
(2022
). “Code for ‘Effects of infection fatality ratio and social contact matrices on vaccine prioritization strategies’,” GitHub. https://github.com/wcota/covid19-vac-st/.© 2022 Author(s). Published under an exclusive license by AIP Publishing.
2022
Author(s)
You do not currently have access to this content.